Octavius Pharma has developed DC granules of Rivaroxaban for making Rivaroxaban plain tablets. Product has been developed to produce uniform particles that help give a better flow-ability in a way that facilitates tablet compression, maintaining content uniformity. Finished tablet qualitative composition and dissolution profile is in line with the Innovator “XARELTO” as per BP monograph.
| Strength | 10 / 15 / 20 mg |
| Finished Dosage Form | Tablets |
| Finished Product Compliance | BP |
| API DMF | Available |
| CTD Dosssier | Available |
Rivaroxaban: Rivaroxaban is indicated in stroke prevention, deep vein thrombosis and pulmonary embolism. It prevents the formation of blood clots in the legs, lungs, brain or heart. Rivaroxaban is a novel oral anticoagulant (NOAC).
GET IN TOUCH
For inquiries and collaboration opportunities, reach out to us today! Your gateway to innovative healthcare solutions awaits!
"*" indicates required fields